Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRR1 | P24046 | 2/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.35 |
| ▸ | GABBR2 | O75899 | 2/20 | 0.31 |
| ▸ | GABBR1 | Q9UBS5 | 2/20 | 0.31 |
| ▸ | TP53 | P04637 | 1/20 | 0.31 |
| ▸ | GSR | P00390 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17909990 | 0.83 | ALDH1A1 (0.36) | ALDH1A1TP53 | |
| SCHEMBL17909993 | 0.81 | ALDH1A1 (0.35) | ALDH1A1TP53 | |
| SCHEMBL5969080 | 0.80 | CA2 (0.41) | ALDH1A1 | |
| SCHEMBL10592678 | 0.80 | CA2 (0.41) | ALDH1A1 | |
| SCHEMBL8028251 | 0.79 | ALDH1A1 (0.48) | ALDH1A1 | |
| SCHEMBL2232837 | 0.79 | ALDH1A1 (0.48) | ALDH1A1 | |
| SCHEMBL16770379 | 0.79 | GABRR1 (0.45) | GABRR1ALDH1A1GABBR2GABBR1GSR | |
| SCHEMBL6207891 | 0.79 | ALDH1A1 (0.48) | ALDH1A1 | |
| SCHEMBL17909976 | 0.77 | ALDH1A1 (0.35) | ALDH1A1TP53 | |
| SCHEMBL10521929 | 0.76 | ALDH1A1 (0.34) | ALDH1A1TP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180094031-A1 | CYCLOSPORIN DERIVATIVES WHEREIN THE MEBMT SIDECHAIN HAS BEEN CYCLIZED | ALLERGAN, INC. | 2018-04-05 | — | — | US | disclosed |
| US-9914755-B2 | Cyclosporin derivatives wherein the MeBmt sidechain has been cyclized | ALLERGAN, INC. (US) | 2018-03-13 | — | — | US | disclosed |
| WO-2016112321-A1 | CYCLOSPORIN DERIVATIVES WHEREIN THE MEBMT SIDECHAIN HAS BEEN CYCLIZED | ALLERGAN, INC. (US) | 2016-07-14 | — | — | WO | disclosed |
| US-20160200767-A1 | CYCLOSPORIN DERIVATIVES WHEREIN THE MEBMT SIDECHAIN HAS BEEN CYCLIZED | ALLERGAN, INC. | 2016-07-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180094031-A1 | CYCLOSPORIN DERIVATIVES WHEREIN THE MEBMT SIDECHAIN HAS BEEN CYCLIZED | CHP1, PPIB, FKBP1B | GABRR1 867/4885ALDH1A1 3455/4885GABBR2 2185/4885 |
| US-20160200767-A1 | CYCLOSPORIN DERIVATIVES WHEREIN THE MEBMT SIDECHAIN HAS BEEN CYCLIZED | CHP1, PPIB, FKBP1B | GABRR1 867/4885ALDH1A1 3455/4885GABBR2 2185/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.